Furthermore, the validation experiments in vivo and in vitro revealed the underlying mechanism of AC484 in the disruption of mitochondrial function and TFRC‐mediated PINK1‐PRKN‐dependent mitophagy, providing the basis for future clinical trials of AC484 in ALK+ ALCL. This evidence concerns the gene PINK1 and anaplastic large cell lymphoma.